Cargando…

New Approaches in Nanomedicine for Ischemic Stroke

Ischemic stroke, caused by the interruption of blood flow to the brain and subsequent neuronal death, represents one of the main causes of disability in developed countries. Therapeutic methods such as recanalization approaches, neuroprotective drugs, or recovery strategies have been widely develope...

Descripción completa

Detalles Bibliográficos
Autores principales: Correa-Paz, Clara, da Silva-Candal, Andrés, Polo, Ester, Parcq, Jérôme, Vivien, Denis, Maysinger, Dusica, Pelaz, Beatriz, Campos, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161190/
https://www.ncbi.nlm.nih.gov/pubmed/34065179
http://dx.doi.org/10.3390/pharmaceutics13050757
_version_ 1783700451688972288
author Correa-Paz, Clara
da Silva-Candal, Andrés
Polo, Ester
Parcq, Jérôme
Vivien, Denis
Maysinger, Dusica
Pelaz, Beatriz
Campos, Francisco
author_facet Correa-Paz, Clara
da Silva-Candal, Andrés
Polo, Ester
Parcq, Jérôme
Vivien, Denis
Maysinger, Dusica
Pelaz, Beatriz
Campos, Francisco
author_sort Correa-Paz, Clara
collection PubMed
description Ischemic stroke, caused by the interruption of blood flow to the brain and subsequent neuronal death, represents one of the main causes of disability in developed countries. Therapeutic methods such as recanalization approaches, neuroprotective drugs, or recovery strategies have been widely developed to improve the patient’s outcome; however, important limitations such as a narrow therapeutic window, the ability to reach brain targets, or drug side effects constitute some of the main aspects that limit the clinical applicability of the current treatments. Nanotechnology has emerged as a promising tool to overcome many of these drug limitations and improve the efficacy of treatments for neurological diseases such as stroke. The use of nanoparticles as a contrast agent or as drug carriers to a specific target are some of the most common approaches developed in nanomedicine for stroke. Throughout this review, we have summarized our experience of using nanotechnology tools for the study of stroke and the search for novel therapies.
format Online
Article
Text
id pubmed-8161190
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81611902021-05-29 New Approaches in Nanomedicine for Ischemic Stroke Correa-Paz, Clara da Silva-Candal, Andrés Polo, Ester Parcq, Jérôme Vivien, Denis Maysinger, Dusica Pelaz, Beatriz Campos, Francisco Pharmaceutics Review Ischemic stroke, caused by the interruption of blood flow to the brain and subsequent neuronal death, represents one of the main causes of disability in developed countries. Therapeutic methods such as recanalization approaches, neuroprotective drugs, or recovery strategies have been widely developed to improve the patient’s outcome; however, important limitations such as a narrow therapeutic window, the ability to reach brain targets, or drug side effects constitute some of the main aspects that limit the clinical applicability of the current treatments. Nanotechnology has emerged as a promising tool to overcome many of these drug limitations and improve the efficacy of treatments for neurological diseases such as stroke. The use of nanoparticles as a contrast agent or as drug carriers to a specific target are some of the most common approaches developed in nanomedicine for stroke. Throughout this review, we have summarized our experience of using nanotechnology tools for the study of stroke and the search for novel therapies. MDPI 2021-05-20 /pmc/articles/PMC8161190/ /pubmed/34065179 http://dx.doi.org/10.3390/pharmaceutics13050757 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Correa-Paz, Clara
da Silva-Candal, Andrés
Polo, Ester
Parcq, Jérôme
Vivien, Denis
Maysinger, Dusica
Pelaz, Beatriz
Campos, Francisco
New Approaches in Nanomedicine for Ischemic Stroke
title New Approaches in Nanomedicine for Ischemic Stroke
title_full New Approaches in Nanomedicine for Ischemic Stroke
title_fullStr New Approaches in Nanomedicine for Ischemic Stroke
title_full_unstemmed New Approaches in Nanomedicine for Ischemic Stroke
title_short New Approaches in Nanomedicine for Ischemic Stroke
title_sort new approaches in nanomedicine for ischemic stroke
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161190/
https://www.ncbi.nlm.nih.gov/pubmed/34065179
http://dx.doi.org/10.3390/pharmaceutics13050757
work_keys_str_mv AT correapazclara newapproachesinnanomedicineforischemicstroke
AT dasilvacandalandres newapproachesinnanomedicineforischemicstroke
AT poloester newapproachesinnanomedicineforischemicstroke
AT parcqjerome newapproachesinnanomedicineforischemicstroke
AT viviendenis newapproachesinnanomedicineforischemicstroke
AT maysingerdusica newapproachesinnanomedicineforischemicstroke
AT pelazbeatriz newapproachesinnanomedicineforischemicstroke
AT camposfrancisco newapproachesinnanomedicineforischemicstroke